| ADT | Androgen deprivation therapy |
| ARPI | Androgen receptor pathway inhibitor |
| ATC | Anatomical therapeutic chemical classification |
| BMI | Body mass index |
| CI | Confidence interval |
| CRPC | Castration-resistant prostate cancer |
| EAU | European Association of Urology |
| EMA | European Medicines Agency |
| EMR | Electronic medical records |
| ESMO | European Society for Medical Oncology |
| HSPC | Hormone-sensitive prostate cancer |
| ICD | International Classification of Diseases |
| IQR | Interquartile range |
| L | Line (treatment line) |
| m | Metastatic |
| mCRPC | Metastatic castration-resistant prostate cancer |
| mHSPC | Metastatic hormone-sensitive prostate cancer |
| nm | Non-metastatic |
| nmCRPC | Non-metastatic castration-resistant prostate cancer |
| OS | Overall survival |
| PC | Prostate cancer |
| PSA | Prostate-specific antigen |
| Q1 | First quartile |
| Q3 | Third quartile |
| RECORD | REporting of studies Conducted using Observational Routinely-collected health Data |
| RT | Radiotherapy |
| SD | Standard deviation |
| SEOM | Sociedad Española de Oncología Médica |
| T | Tumor |
| TNM | Tumor, node, and metastasis classification |
| TURP | Transurethral resection of the prostate |